INTRODUCTION
In 2016, nearly 250,000 women were expected to have been diagnosed with breast cancer, and more than 40,000 were expected to have died from the disease. 1 Although breast cancer is amenable to screening, a large percentage of women (38%) continue to be diagnosed with advanced-stage disease, 1 when the prognosis is poor. A low socioeconomic status has been strongly implicated in cancer-related disparities. 2, 3 In addition, racial disparities in breast cancer screening, 4, 5 stage, 6, 7 tumor biology, 8, 9 treatment, 7, [10] [11] [12] and survival outcomes 7, 9, 13, 14 have been well documented. Health insurance is a key motivator not only for seeking cancer-screening services 15 and receiving cancer care, 3 especially among women of ethnic/racial minority backgrounds, [16] [17] [18] but also for obtaining timely diagnostic follow-up after a positive screening mammogram. 19 The Breast and Cervical Cancer Early Detection Program (BCCEDP), initiated by the Centers for Disease Control and Prevention, is an organized screening program that has played a central role in improving breast cancer outcomes among underserved women since the early 1990s. [20] [21] [22] [23] [24] [25] The Ohio BCCEDP provides coverage for clinical breast examination to women 40 to 49 years old and for screening mammography to women 50 to 64 years old as long as they are uninsured and their income falls at or below 200% of the federal poverty level. Importantly, the BCCEDP provides coverage for diagnostic testing in cases of abnormal findings; and thanks to the 2000 Breast Cancer Treatment Act, women diagnosed with breast or cervical cancer (or precancerous cervical lesions) through the BCCEDP automatically receive treatment coverage through Medicaid. 26 In addition, the Centers for Disease Control and Prevention has core performance indicators and standards by which it evaluates its BCCEDP grantees. 27 For breast cancer, these indicators include the following: abnormal screening results with complete follow-up (performance standard at 90%), time from abnormal screening results to a final diagnosis > 60 days (25%), treatment started for breast cancer (90% within 9 months postscreening), and time from the diagnosis of breast cancer to the start of treatment > 60 days (20%). 27 To gain a better understanding of the BCCEDP's role in the state's efforts to reduce breast cancer disparities, we compared breast cancer stage and mortality across 1) BCCEDP 1-time and repeat users, 2) Medicaid beneficiaries (distinguishing between those who had been in Medicaid before their cancer diagnosis [prediagnosis beneficiaries] and those enrolling in Medicaid around the time of their cancer diagnosis [peridiagnosis beneficiaries]), 28, 29 and 3) all others (identified neither as BCCEDP participants nor as Medicaid beneficiaries). We hypothesized the following: 1) BCCEDP women would experience more favorable breast cancer stage and mortality outcomes than Medicaid beneficiaries; 2) although the most favorable outcomes would be observed among non-BCCEDP women and non-Medicaid women, the most vulnerable women would be identified in the Medicaid/peridiagnosis group; and 3) BCCEDP repeat users would experience more favorable outcomes than BCCEDP 1-time users.
MATERIALS AND METHODS
This was a retrospective cohort analysis using multiple sources of data, including the Ohio Cancer Incidence Surveillance System (OCISS), Ohio BCCEDP, Ohio Medicaid enrollment files, US Census, and Ohio death certificates.
This study was approved by the Ohio Department of Health, the Ohio Department of Medicaid, and the institutional review board at Case Western Reserve University.
Data Sources

OCISS
Launched in the early 1990s, the OCISS was designed to capture all incident cases of cancer diagnosed among Ohio residents with the exception of carcinoma in situ of the cervix uteri as well as basal cell carcinoma and squamous cell carcinoma of the skin. The rate of completeness for female breast cancer during the study period was estimated to be 88% for the years 2000-2004, and 90% in more recent years, according to reports available through the OCISS Web site (http://www.odh.ohio.gov/health/cancer/ocisshs/ newrpts1.aspx). Accessed December 23, 2016 .
The OCISS includes the anatomic cancer site as well as tumor characteristics, including the Surveillance, Epidemiology, and End Results summary stage. Although the variables on tumor size (T), number of lymph nodes (N), and metastasis (M) are available in the OCISS, these variables have a high percentage of missing values for the study years. Hence, we used the Surveillance, Epidemiology, and End Results (SEER) summary stage.
In addition to patient identifiers and demographics, the OCISS also carries the date of diagnosis and the residence address at the time of diagnosis.
Data from the OCISS were used to identify women diagnosed with incident invasive breast cancer during the years 2002-2008. We used each patient's geocoded address from the OCISS to obtain socioeconomic characteristics from US Census data.
BCCEDP
The BCCEDP database includes several files. In addition to identifiers and demographics, it includes records for each of the encounters that a given participant has had with the program; this makes it possible to identify BCCEDP 1-time and repeat users.
Ohio Medicaid enrollment files
These files include monthly variables indicating beneficiaries' enrollment in the program. In addition, because women diagnosed with cancer through the BCCEDP are automatically eligible to receive health care and cancer treatment coverage through Medicaid, one of the eligibility categories in Medicaid enrollment files is BCCEDP. Because our study population includes women diagnosed with breast cancer through the BCCEDP rather than only those screened through the program, we identified BCCEDP participants through the Medicaid enrollment files.
Once the OCISS and Medicaid enrollment files were linked, the date of diagnosis from the OCISS was used to construct each woman's enrollment history in Medicaid with respect to her cancer diagnosis and to identify Medicaid beneficiaries in the Medicaid/prediagnosis and Medicaid/peridiagnosis categories.
Data from the US Census
Socioeconomic data at the census block group level, including data on income, educational attainment, employment, and female-headed households, were retrieved from the US Census American Community Survey on the basis of geocoded information from the OCISS.
Ohio death certificates
Death certificates were used to ascertain each study participant's vital status and to retrieve the date and cause of death. According to a report by the National Vital Statistics System on 2010 data, 30 the demographic file of Ohio death certificates, confirming the vital status, was available for 100% of decedents who were residents of the state. The medical file, which would include the cause of death, was available for 97% of the decedents.
Data linkage
Data from the OCISS, BCCEDP, Ohio Medicaid enrollment files, and death certificates were linked with patient identifiers (first and last names, date of birth, and Social Security number) with a multistep deterministic algorithm, as previously described. 28 
Study Population
Our study population included all women 40 to 64 years old who were residing in Ohio and were diagnosed with incident invasive breast cancer during the years 2002-2008 (n 5 27,201). We excluded women with unstaged/ unknown-stage cancer (n 5 775), and this left our study population at 26,426.
Variables of Interest
Outcome variables
The outcome variables were as follows:
1. Advanced-stage cancer at diagnosis. This was defined as regional-or distant-stage disease at diagnosis. 2. Survival. We calculated overall and cancer-specific survival on the basis of the date and cause of death retrieved from death certificate files.
Independent variables
Our main independent variables were the BCCEDP and Medicaid status, which included the following 5 mutually exclusive categories ( Fig. 1 ):
1. BCCEDP 1-time users. 2. BCCEDP repeat users. 3. Medicaid/prediagnosis group (women who were enrolled in Medicaid at least 3 months before their cancer diagnosis). 4. Medicaid/peridiagnosis group (women who were enrolled in Medicaid upon being diagnosed with cancer or within the 3-month window around the date of their cancer diagnosis). 5. All others (women who were neither BCCEDP participants nor Medicaid beneficiaries).
Other independent variables included the following: age (40-49, 50-59, or 60-64 years), race (African American vs all others), marital status (married vs unmarried), and socioeconomic status (at the census block group level, a composite variable developed by normalization of the percentage of individuals with incomes below 100% of the federal poverty level, the percentage of adults with no high-school diploma, the unemployment ratio, and the percentage of female-headed households). The composite measure for socioeconomic status was categorized in .01 P < .05. To safeguard study subjects' privacy, '-' was used to mask cells < 11. Other cells within the same row or column were also masked to prevent the reader from deriving the masked numbers.
Original Article quartiles, with the fourth quartile reflecting the poorest or most disadvantaged group. Finally, we included a binary variable indicating residence in a medically underserved area and a variable indicating residence according to the type of county (Appalachian/rural, metro, or suburban).
Analysis
In addition to a descriptive analysis, we compared the association between the BCCEDP and Medicaid status and each of the outcomes of interest before and after adjustments for potential confounders. In our main multivariable logistic regression and Cox proportional hazards survival models, we designated the all others category (or non-BCCEDP and non-Medicaid women) as the reference group. However, we also compared the following groups: 1) BCCEDP 1-time users versus BCCEDP repeat users, 2) BCCEDP 1-time users versus the Medicaid/prediagnosis group, and 3) BCCEDP repeat users versus the Medicaid/prediagnosis group. Our model for analyzing the cancer stage included all variables listed in Table 1 with the exception of the cancer stage. The survival models accounted for all the variables listed in Table 1 . With respect to survival outcomes, we present the Kaplan-Meier curves in Figure 2A ,B, which show that survival was worst for the Medicaid/peridiagnosis group. In multivariable analyses, we observed no statistically significant differences between BCCEDP women and all others for either overall or cancer-specific survival. We note, however, the adjusted hazard ratios (AHRs) greater than 1.0 for BCCEDP 1-time users ( The following summarizes the relevant comparisons across the various subgroups of the population. First, compared with BCCEDP repeat users, BCCEDP 1-time users were significantly more likely to be diagnosed with advanced-stage disease and to experience worse overall survival. Although the AHR for cancer-specific survival was 2.17, it did not reach statistical significance. Second, compared with Medicaid/prediagnosis women, those in the Medicaid/peridiagnosis group were twice as likely to be diagnosed with advanced-stage disease (AOR, 2.20; 95% CI, 1.83-2.66); however, survival outcomes were similar among women in the Medicaid/peridiagnosis group and did not reach statistical significance. Third, compared with Medicaid/prediagnosis women, BCCEDP 1-time users were significantly more likely to be diagnosed with advanced-stage disease (AOR, 1.48; 95% CI, 1.17-1.87) but experienced better overall survival outcomes (AHR, 0.60; 95% CI, 0.45-0.80) and cancer survival outcomes (AHR, 0.77; 95% CI, 0.57-1.06), albeit not at a statistically significant level. Finally, compared with Medicaid/prediagnosis women, BCCEDP repeat users were as likely to be diagnosed with advanced-stage disease (AOR, 0.83; 95% CI, 0.59-1.18) but experienced significantly better survival outcomes (AHR for overall survival, 0. 
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DISCUSSION
To gain a better understanding of the BCCEDP's role in reducing breast cancer disparities, we compared breast cancer stage and survival outcomes across subgroups of Medicaid beneficiaries and BCCEDP participants and all others. Among the 4 Medicaid and BCCEDP subgroups of women with breast cancer, the group that experienced outcomes that most closely compared with those of all others was BCCEDP repeat users. Interestingly, however, stage outcomes were worse among BCCEDP 1-time users than women in the Medicaid/prediagnosis group, and this perhaps suggests that women receiving coverage through Medicaid for an extended period of time may have received screening mammography on a somewhat more regular basis than their 1-time BCCEDP counterparts. Indeed, as shown previously, 31, 32 longer spans of enrollment in Medicaid are associated with an increased likelihood of receiving screening mammography. In addition, it is possible that 1-time BCCEDP users were more likely than Medicaid/prediagnosis beneficiaries to undergo diagnostic mammography rather than screening mammography, although that remains to be explored.
In agreement with our and others' previous studies, 28, 29, [33] [34] [35] women in the Medicaid/peridiagnosis group represented the most vulnerable subgroup of our study population: more than 1 in 5 women (21.9%) in the Medicaid/peridiagnosis group presented with metastatic disease. This percentage is nearly 3 times that observed among Medicaid/prediagnosis beneficiaries and BCCEDP 1-time users (7.0% and 7.7%, respectively) and 5 times that for non-Medicaid/non-BCCEDP women (4.3%).
These statistics are very alarming. Additional studies are needed to identify the health care barriers specific to this subgroup of breast cancer patients to gain a better understanding of the circumstances in which their cancer is diagnosed. Although it is highly likely that a lack of insurance greatly hinders access to screening and early detection, providing women insurance will not, by itself, address the many barriers that drive racial/ethnic and income-related cancer disparities. With their highly desirable features (eg, reminder systems), programs such as the BCCEDP are essential for early breast cancer detection 36 despite their limited reach to eligible women. 20 In addition, however, it is critically important for the Medicaid program to improve access to screening and treatment services not only for its beneficiaries but also for the nearly poor who might potentially enroll in Medicaid. Although the impact of Medicaid expansion through the Patient Protection and Affordable Care Act has not yet been evaluated, this policy action may have been a very important step toward addressing health care barriers. The benefits of having insurance for cancer-specific survival have been documented, especially in disadvantaged communities 37 ; however, disparities related to social determinants of health cannot be addressed by health insurance alone. 37 Integrated efforts across policy, clinical health care, and community-based efforts are needed to address barriers to high-quality screening and treatment services, and to eliminate disparities. 38 In addition to its use of an integrated database to identify Medicaid and BCCEDP enrollees, an important methodological strength of this study lies in the categorization of Medicaid beneficiaries in the prediagnosis and peridiagnosis groups and of BCCEDP users as 1-time or repeat users. The fact that outcomes differ to such a great extent across these groups underscores the importance of making these distinctions. The dichotomous categorization of the BCCEDP variable may hide the fact that stage outcomes are comparable between BCCEDP 1-time users and women in the Medicaid/prediagnosis group and also that BCCEDP repeat users experience outcomes similar to those of non-Medicaid/non-BCCEDP women. 39 The favorable outcomes among BCCEDP repeat users point clearly to the benefits of having a system that encourages regular screening 40 and one that provides subsequent navigation to expedite the diagnostic resolution of abnormal findings and treatment initiation. These findings need to be analyzed more closely to identify the specific features of the BCCEDP to which these favorable outcomes can be attributed.
Our findings must be interpreted in light of the following limitations. First, with the exception of women in the Medicaid/prediagnosis group, we note the absence of claims data preceding the cancer diagnosis and our inability to capture comorbid conditions and incorporate them into our analyses. This might explain the most unfavorable (overall) survival outcomes among women in the Medicaid/prediagnosis group, many of whom might have experienced complex medical and psychosocial problems (factors for which our multivariable models could not be adjusted). Second, although mammography examinations could be identified by indication (screening vs diagnostic) from the BCCEDP and, to some extent, claims data, it was not possible to flag the receipt of mammography, even without a distinction being made by indication, among all of the 5 comparison groups. Consequently, this key measure could not be used in our analysis. Third, although it would have been desirable to have a longer follow-up period to capture mortality, we were restricted to a relatively short study period, mostly because of logistical issues. Fourth, because of the limitations of our data sources, women in the all others group were those who were not identified as Medicaid or BCCEDP enrollees. Therefore, the all others group was a heterogeneous group and included both privately insured and under/ uninsured women. However, because the representation of under/uninsured women in that group was relatively low (estimated at 10.7% in Ohio's population at large during the years 2004-2006), 41 their statistics may have been diluted to a great extent by those of women with private insurance, and this may have masked unfavorable outcomes among the under/uninsured. 42 Cancer outcomes should be studied closely in this vulnerable subgroup of women to inform the development of targeted cancer-screening programs. Lastly, we note our use of socioeconomic variables at the census block group level rather than the individual level. However, it has been shown that socioeconomic data at small geographical levels may be extrapolated to the individual level. 43 In summary, our findings point clearly at unacceptably high percentages of metastatic disease at diagnosis among women in the Medicaid/peridiagnosis group. In addition to conducting qualitative analyses to understand the circumstances under which these women are diagnosed with breast cancer and then referred to Medicaid, future studies should determine the impact of the Patient Protection and Affordable Care Act and the movement of women of different income levels across Medicaid, the BCCEDP, private insurance, and an uninsured status with respect to breast cancer early detection and outcomes.
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